# Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer

> **NCT02535338** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 11 (actual)

## Conditions studied

- Recurrent Lung Non-Small Cell Carcinoma
- Stage IV Lung Non-Small Cell Cancer AJCC v7

## Interventions

- **DRUG:** Erlotinib Hydrochloride
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Onalespib Lactate
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT02535338
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-11
- **Primary completion:** 2021-09-03
- **Final completion:** 2021-09-08
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2025-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02535338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02535338, "Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02535338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*